Last week, CHPA, the American Herbal Products Association, the Council for Responsible Nutrition, and the United Natural Products Alliance sent a letter to Senators Tammy Baldwin (D-Wisc.) and John Hoeven (R-N.D.), the Chair and Ranking Member of the Appropriations Subcommittee that has jurisdiction over FDA funding, highlighting the need for additional resources for the Office of Dietary Supplement Programs at FDA due to the growing dietary supplement market.
CHPA released the following statement in response to new research published in Clinical Toxicology. The study found nine illegal stimulants, including deterenol, in fraudulently marketed sports and weight loss supplements.
CHPA released the following statement in response to FDA’s warning that consumers avoid certain male enhancement and weight loss products sold by major online retailers due to hidden, potentially dangerous drug ingredients.
CHPA submitted comments this week to the Food and Drug Administration regarding the proposed development of an authorized list of dietary ingredients marketed prior to the Dietary Supplement Health and Education Act.
Echoing earlier comments submitted to the agency, CHPA and its member companies marketing dietary supplement products support the presumption of safety for dietary ingredients outlined in the 1994 passage of DSHEA.
The industry favors and supports the development of reasonable guidance. However, the agency’s attempt to redefine the NDI notification process contradicts the letter and spirit of DSHEA. The Draft Guidance would undo nearly two decades of agency practice and policy.